Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000950170-25-004311
Filing Date
2025-01-10
Accepted
2025-01-10 17:34:57
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 15361
2 EX-99.1 ck0001597553-ex99_1.pdf EX-99.1 82142
3 EX-99.4 ck0001597553-ex99_4.pdf EX-99.4 121693
4 EX-99.I ck0001597553-ex99_i.pdf EX-99.I 86726
  Complete submission text file 0000950170-25-004311.txt   418014
Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142
Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
BIOGEN INC. (Filed by) CIK: 0000875045 (see all company filings)

EIN.: 330112644 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Subject) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-88275 | Film No.: 25524104
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)